Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01804140 · BASELINE

Baseline characteristics

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) · Source last updated 2016-11-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      548
    units
    Participants
groups
  1. description
    Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.
    id
    BG000
    title
    Participants With Confirmed Solid Tumors or Multiple Myeloma
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          12.38
          value
          63.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          326
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          222
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
All the participants who were enrolled and were evaluable for the BRAF V600 mutations were included in the analysis.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      548
    units
    Participants
groups
  1. description
    Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.
    id
    BG000
    title
    Participants With Confirmed Solid Tumors or Multiple Myeloma
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          12.38
          value
          63.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          326
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          222
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
All the participants who were enrolled and were evaluable for the BRAF V600 mutations were included in the analysis.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice